Keyword :
Select Report Type :
Select Industry :
Select Sector :
Select Category :
Select Geography :

Search Results

Report Title
Price
Global Oncology Market - Trends, Forecast and Pipeline Analysis   $7,219
  • Language: English | #Pages: 280 | Published: Nov-2014 | Region: Global
Single User price :$7,219 Add To Cart
Enterprise Price :$14,509 Add To Cart
Global Corporate Price :$21,637 Add To Cart

 Global Oncology Market to hit $109 billion – Spotlight on Drug Life Cycle Management, M&A and Pipeline Strategies

  • 18 drugs constitute ~75% of the global oncology market; one-third of these drugs are growing annually above 30%  
  • VEGF (Vascular Endothelial Growth Factor) is the mascot among top targets/pathways

Cancer, with a death toll exceeding that of AIDS (Acquired Immune Deficiency Syndrome), tuberculosis and malaria collectively, accounted for 8.3 million deaths in 2013. With a skyrocketing incidence of 469.6 per 100,000 in the US alone, the oncology market is poised to grow at a substantial CAGR of around seven percent to $109 billion by 2020. Targeted therapy class is the ‘top dog’ among all therapy segments with nearly ~3x the combined market of cytotoxic and hormonal therapy. “Growth factors such as EGF (Epidermal Growth Factors) and VEGF govern around half of the oncology therapy market, and have changed the landscape of pipeline and LCM (Life Cycle Management) strategies, outstripping the orthodox indications approach,” said ABMRG’s analyst Hardik Sharma. Although in last two years, a plethora of targeted drugs has been launched and is in development, price pressures have started popping up due to high scrutiny from payers, physicians and governments.

F. Hoffmann-La Roche AG ($RHHBY), Novartis AG ($NVS) and Celgene Corporation ($CELG) are the top three players, collectively accounting for ~70% of the entire market, followed by Johnson & Johnson ($JNJ), AstraZeneca plc (NYSE: AZN; LSE: AZN), Bristol-Myers Squibb ($BMY) and Pfizer, Inc ($PFE).  Other major players include Merck & Co. Inc. ($MRK), GlaxoSmithKline plc ($GSK), Eli Lilly and Company ($LLY), Bayer AG ($BAYN), Amgen ($AMGN), AbbVie ($ABBV), Sanofi S.A. ($SAN).

With almost every drug growing annually above 10%, Roche is the market leader and front-runner in life-cycle management of oncology drugs, as it holds the highest number of in-line extensions (ILEs), which comprise around half of its entire pipeline. The words of Roche CEO Severin Schwan—“We go where the science takes us”—demonstrates its focus on bolt-on acquisitions compared with a transformational approach. Celgene also shares the same philosophy as evident from its recent deal with OncoMed.

Novartis, which has the most robust oncology pipeline with multi-fold NMEs than Roche, has adopted multi-pronged—bolt-on and transformational—growth strategy. This is evident from its recent $90 million deal with Oxford Biomedica for boosting its cancer immunotherapy portfolio and the acquisition of complete oncology unit of GlaxoSmithKline plc.

“In an era of consolidation, where companies like Novartis acquired oncology business of GSK and Pfizer made endless attempts to buy out AstraZeneca, at least a couple of M&As in oncology space are expected in the short term by pharma juggernauts eying on the high-growth oncology market to overcome the ‘dried-up’ pipelines and looming patent expirations,” said ABMRG CEO Manoj Jiandani.

Avastin is the leader with sales of $6.7 billion in 2013 and in the short- to mid-term it is forecast to sustain its position supported by its extensive pipeline and entrenched indications base. Meanwhile, in the long term, Revlimid is expected to dominate due to its extensive pipeline, prolonged patent term and impressive CAGR of more than 40%.

Global cancer burden is expected to get nearly doubled to more than 21 million cases and 13 million deaths by 2030. Owing to high unmet needs, the oncology market would continue to grow at a moderate pace, driven by rising aging population, hopping incidence rates, expedited FDA approvals, booming urbanisation, enhanced diagnosis and rising adoption of combination therapies. Conversely, sky-high prices, limited reimbursement, high patient out-of-pocket costs and lack of screening and awareness in developing regions are the major restraints.

Although, cancer continues to be a major health challenge in the developed world, driven by modern lifestyle patterns, more than 60% of world’s new annual cases originate from Africa, Asia and Central and South America, which together account for nearly three-fourths of the world’s cancer deaths. Among developing economies, India, China and Russia account for ~40% of world’s population with around 2x the cancer mortality rates compared with that in the US and the UK.

Key Questions Answered:

 

  • Which are the probable game-changers in terms of drug, therapy class and player?
  • Which are the high-growth segments and expected potential targets/pathways?
  • Which are the top 35 oncology drugs and leading market players globally?
  • How did new drugs evolve into blockbusters and what are the strategies behind it?
  • What is the estimated market size and market forecast?
  • What are the major market drivers and restraints globally and in key geographies?
  • How is the competitive outlook in terms of key products, pipeline and players?
  • What are unmet needs and opportunities in the oncology market?

Russia Mammography Systems Market Trends Forecast to 2020   $3,700
  • Language: English | #Pages: 30 | Published: Nov-2014 | Region: Global
Single User price :$3,700 Add To Cart
Enterprise Price :$7,400 Add To Cart
Global Corporate Price :$11,100 Add To Cart
Germany Medical Imaging Market Opportunity and Growth Trend Forecast Till 2020   $3,700
  • Language: English | #Pages: 80 | Published: Nov-2014 | Region: Global
Single User price :$3,700 Add To Cart
Enterprise Price :$7,400 Add To Cart
Global Corporate Price :$11,100 Add To Cart

  

Asia Pacific Medical Imaging Market Growth and Forecast To 2020   $5,500
  • Language: English | #Pages: 172 | Published: Nov-2014 | Region: Global
Single User price :$5,500 Add To Cart
Enterprise Price :$11,000 Add To Cart
Global Corporate Price :$16,500 Add To Cart
France Mammography Systems Market Trends Forecast to 2020   $3,520
  • Language: English | #Pages: 30 | Published: Nov-2014 | Region: Global
Single User price :$3,520 Add To Cart
Enterprise Price :$7,040 Add To Cart
Global Corporate Price :$10,560 Add To Cart
China Mammography Systems Market Forecast and Opportunity Assessment, 2007-2020   $3,610
  • Language: English | #Pages: 30 | Published: Nov-2014 | Region: Global
Single User price :$3,610 Add To Cart
Enterprise Price :$7,220 Add To Cart
Global Corporate Price :$10,830 Add To Cart
Australia Medical Imaging Market Trends Forecast, 2014   $3,700
  • Language: English | #Pages: 80 | Published: Nov-2014 | Region: Global
Single User price :$3,700 Add To Cart
Enterprise Price :$7,400 Add To Cart
Global Corporate Price :$11,100 Add To Cart

 ..

Single User price :$2,900 Add To Cart
Enterprise Price :$5,800 Add To Cart
Global Corporate Price :$8,700 Add To Cart
This research report provides key market trends, market forecasts and competitive scenario of the Cerebral Spinal Fluid Management Devices (CSF) in China through 2020.
 
 The product categories covered in this report include: 
 
 •  CSF Shunt
 
 •  ICP Monitoring Devices
 
 Scope
 
The report highlights historic and forecasted market size in terms of revenues & unit sales, average selling price, growth rates, and company market shares. 
 
• Highlights and compares key product categories for growth trends and revenue forecast.
 
• Market size, annualized revenue and unit sales for each product category from 2007 to 2020.
 
• Cross category comparison - Growth and revenue comparison for product categories, historic and forecast through 2020. 
 
• Market share of companies.
 
• Average selling price ($) for each product type (2007 to 2020).
 
• Recent Events and Developments.
 
 Why should you buy?
 
• Build business strategy by identifying the high growth and attractive market categories. 
 
• Develop competitive strategy based on competitive landscape. 
 
• Design capital investment strategies based on forecasted high potential segments. 
 
• Identify potential business partners, acquisition targets and business buyers. 
 
• Plan for a new product launch and inventory in advance. 
 
• Prepare management and strategic presentations using the market data. 
 

• To review unbiased and independent assessment of the market data.  

Australian Diabetes Management Devices Market, 2007 - 2020   $4,249
  • Language: English | #Pages: 55 | Published: Nov-2014 | Region: Global
Single User price :$4,249 Add To Cart
Enterprise Price :$8,498 Add To Cart
Global Corporate Price :$12,747 Add To Cart

The Australian Diabetes Management and Diabetes Diagnostic Devices market jumped by $46 millionbetween 2005 and 2013. The market comprises continuous glucose monitors (CGM), self-monitoring blood glucose (SMBG), manual insulin delivery products, glucose test strips, lancets, syringes, insulin pens and insulin pumps. The growth is driven by the high prevalence of diabetes, acceptance and proliferation of advanced patient compliant technologies, increased reimbursement of devices and government subsidy on consumables. Especially, continuous glucose monitors (CGM), self-monitoring blood glucose (SMBG) and manual insulin delivery products exhibited significant market growth.

The prevalence of diabetes in Australia has skyrocketed three times to 4.2% over the last 25 years. Around 1 million people in country suffer from diabetes and around 2 million have pre-diabetes. Of these, 11% have type 1 diabetes, 87% have type 2 diabetes and 2% women have gestational diabetes. We estimate that approximately 3.4 million citizens will suffer from diabetes by 2030. This high progression rates in diabetes can be attributed to the growth in elderly population, increased life expectancy, obesity, sedentary life style, unhealthy diet and high stress levels. Further, factors like smoking and physical inactivity have led to increased prevalence of both the types of diabetes in young people.

However, various new technologies for diabetes management have helped reduce adverse events and risk of insulin pump (IP) malfunctioning. This has also promoted the acceptance and adoption of sophisticated products leading to improved patient compliance and better management of diabetes.

The improvement in government initiatives has also fuelled the market growth. Australian government provides approximately 70% reimbursements for glucose test strips under the Pharmaceutical Benefits Scheme (PBS). The Australian Institute for Health and Welfare (AIHW) reports that the number of new Insulin Pump Therapy (IPT) users increased from 107 to 140 per month during the period from 2003 to 2010-pushing up the number of IPT users to 10,510 in 2010. Increased affordability due to the Government's Insulin Pump Program (IPP), subsidized Insulin Pump Consumables (IPC) and private health insurance has contributed to the increased use of IPT over the past 10 years.

Among the key players F. Hoffmann-La Roche AG (ROG: SIX), LifeScan, Inc., a Johnson & Johnson Company (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT) enjoy a major share of the market. Other players include Animas Corporation (Nasdaq: PUMP), ARKRAY, Inc., Bayer HealthCare AG (BAYN: DE), Becton, Dickinson and Company (NYSE: BDX), Eli Lilly and Company (NYSE: LLY), Medtronic, Inc. (NYSE:MDT), Novo Nordisk A/S (Copenhagen: NOVOb.CO - Reuters; NYSE: NVO), Sanofi S.A. (SAN: EN; NYSE:SNY), Smiths Medical, a division of Smiths Group Plc (LSE: SMIN) and Terumo Corporation (TSE: 4543).

'Australian Diabetes Management Devices Market, 2007-2020', a market intelligence report published by ABMRG recently, covers all the major product segments of diabetes devices and provides historical and statistically refined forecast data for the segments covered. It not only puts forth a detailed overview of historical trends and forecasts (2007-2020), the annualized trends for sales in terms of value and volume, market growth, pricing (Average Selling Price or ASP), competitive landscape and market share, but offers a cross-category comparison of historical and forecast periods, market drivers, market restrains and challenges. In addition, it presents an inclusive account of global industry developments for the past two years, including M&As, partnerships, clinical studies, pipeline, product approvals and launches, recalls and litigations, market dynamics and market drivers and restrains.

Why one should buy this report 

The report can be instrumental in making strategic decisions pertaining to:

  • Competitive diabetes product launch
  • Capital investments based on the forecast for high potential diabetes segments.
  • Capitalization of opportunities in high-growth geographies and attractive diabetes markets.
  • Identification of in-licensing and out-licensing opportunities, and recognizing potential business partners and M&A targets within the diabetes market.
  • Procurement of raw material and inventory well in advance for the diabetes equipment companies.
  • Preparation of management and strategic presentations for the investors and shareholders.
  • Managerial presentations to the management.
Europe Diabetes Management Market Outlook Through 2020   $5,509
  • Language: English | #Pages: 140 | Published: Nov-2014 | Region: Global
Single User price :$5,509 Add To Cart
Enterprise Price :$11,018 Add To Cart
Global Corporate Price :$16,527 Add To Cart
The Market Intelligence report provides critical market data for China diabetes management devices market and its product categories. The data includes market size in terms of value and volume; average selling price for each product type, growth trends and market shares of companies at sector and category level. 
 
It s vital cross category comparison and cross sub-category comparison section makes analysis very handy for company professionals. The report helps professionals in mapping market size, competition, understanding historic and future growth trends.
 
It covers important categories such as blood glucose monitoring systems and insulin delivery devices.
 
Market Size 
Market size in terms of value ($) and volume (units), for each level of segmentation from 2006 to 2013 and forecast till 2020. 
 
Market Growth
Market growth in terms of value ($) and volume (units), for each level of segmentation from 2006 to 2013 and forecast till 2020. 
 
Competitive Analysis 
Market share (%) of companies is covered at sector and category level for 2013.
 
Pricing Analysis
Average selling price ($) for each product type from 2006-2013 and forecast till 2020.
 
Cross category comparison and cross sub-category comparison Forecast and historic market growth and market size comparison for various categories and sub-categories from 2006 to 2013 and 2013 to 2020. 
 
Recent events and developments
 
Diabetes Management Devices Market Segmentation
Blood Glucose Monitoring Systems
Blood Glucose Meters
Blood Glucose Test Strips
Continuous Glucose Monitoring Systems
Continuous Glucose Monitors (CGM)
CGM Sensors
Insulin Delivery Devices
Insulin Pens
Reusable Insulin Pens
Disposable Insulin Pens
Insulin Syringes
Insulin Pumps
 

 <<   | <   | 1   | 2   | 3   | 4    5   | 6   | 7   | 8   | >   | >>   

Page 4 of 230   showing records 31 to 40 of 2299 in this selection